A Pyrosequencing Assay for the Quantitative Methylation Analysis of GALR1 in Endometrial Samples: Preliminary Results

Endometrial cancer is the most common malignancy of the female genital tract while aberrant DNA methylation seems to play a critical role in endometrial carcinogenesis. Galanin's expression has been involved in many cancers. We developed a new pyrosequencing assay that quantifies DNA methylatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Kottaridi, Christine, Koureas, Nikolaos, Margari, Niki, Terzakis, Emmanouil, Bilirakis, Evripidis, Pappas, Asimakis, Chrelias, Charalampos, Spathis, Aris, Aga, Evangelia, Pouliakis, Abraham, Panayiotides, Ioannis, Karakitsos, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609388/
https://www.ncbi.nlm.nih.gov/pubmed/26504828
http://dx.doi.org/10.1155/2015/756359
Descripción
Sumario:Endometrial cancer is the most common malignancy of the female genital tract while aberrant DNA methylation seems to play a critical role in endometrial carcinogenesis. Galanin's expression has been involved in many cancers. We developed a new pyrosequencing assay that quantifies DNA methylation of galanin's receptor-1 (GALR1). In this study, the preliminary results indicate that pyrosequencing methylation analysis of GALR1 promoter can be a useful ancillary marker to cytology as the histological status can successfully predict. This marker has the potential to lead towards better management of women with endometrial lesions and eventually reduce unnecessary interventions. In addition it can provide early warning for women with negative cytological result.

Ejemplares similares